

Serk In Park

Curriculum Vitae

Professor
Department of Biochemistry and Molecular Biology, Korea University College of Medicine, Seoul, Korea



● Educational Background & Professional Experience

2015–	Professor and Chairman, Department of Biochemistry & Molecular Biology, Korea University College of Medicine, Seoul, Korea
2012–2015	Tenure-track Assistant Professor, Departments of Medicine and Cancer Biology; Vanderbilt Center for Bone Biology; Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN
2008–2012	Research Fellow, Department of Periodontics and Oral Medicine, The University of Michigan, Ann Arbor, MI (Advisor: Laurie K. McCauley, DDS, PhD)

● Research Interests

Cancer, Bone Metastasis, Bone Marrow Immunology

● Honors & Awards

2025	Research Award, the Korean Endocrine Society
------	--

● Publications

1. Lee JY, Lee EJ, Seo BY, Kim J, Song Y, Lee D, Moon N, Koo H, Park CK, Kim MS, Park SI, Nam DH, Kong DS, Sa JK. Single-cell analysis reveals a longitudinal trajectory of meningioma evolution and heterogeneity. *Nat Commun.* 2025 Jul 1;16(1):5481.
2. Park SH, Yoon DH, Kim JW, Park SI*, Hur J, Park SB*. Deletion of the POLR2J4 Gene in Breast Cancer Cells Promotes Bone Metastatic Tumor Growth. *Anticancer Res.* 2025 Aug; 45(8):3263–3273. (*=Co-Correspondence)
3. Ma R, Kang M, Kim GH, Kang H, Lee S, Yang Y, Lee HJ, Choi S, Kim S, Kim S, Jun Y, Kim H, Zhang Y, Kim US, Kang HR, Kim Y, Lee Y, Chung W, Lee EJ, Park SI, Kim E, Jeon M, Hwang GS, Choi J, Jung Y, Kim JY, Kim E, Lee KJ, Han K. Seizure evolution in a mouse model of West syndrome involves complex and time-dependent synapse remodeling, gliosis and alterations in lipid metabolism. *PLoS Biol.* 2025 Oct 9;23(10):e3003192.
4. Ju HY, Yoon H, Jung S, Park SI*, Kim TK*, Han MR*. Systematic chemotherapy in metastatic TNBC polarizes effector T cell differentiation. *Cancer Cell Int.* 2025 Oct 22; 25(1):371(*=Co-Correspondence).
5. Yun DH, Kim JH, Lee SH, Lee EJ, Park SI*, Song YS*. Human adipose stem cells engineered to express carboxylesterase confer anti-tumoral efficacy of irinotecan in castration-resistant prostate cancer bone metastasis growth and osteolysis. *World J Mens Health.* 2026 April 1;44(2):359–369 (*=Co-Correspondence).